Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe proliferative diabetic retinopathy.
OBJECTIVE
To examine the evolution and complications of preretinal hemorrhage under silicone oil after diabetic vitrectomy.


METHODS
A total of 44 cases of primary diabetic vitrectomy with silicone oil infusion were reviewed in a 3-year period. Intravitreal bevacizumab was used preoperatively for cases with active proliferation, and in all cases at the end of surgery. Intraoperative bleeding, postoperative extent of preretinal hemorrhage, blood reabsorption time, and reproliferation and treatment results were assessed.


RESULTS
Maximal blood distributed in thin and scattered patterns (23 cases), thick and localized patterns (10 cases), or thick and scattered patterns (10 cases) developed within 1 week after surgery, and was largely reabsorbed within a month with improved postoperative vision. Confluent blood extending to the midperiphery (one case) resulted in severe fibrosis and detachment. Complications included fibrotic plaque (two cases), and fibrous band and thick membrane (seven cases). Six cases underwent preretinal tissue removal. Vision improvement ≥ 3 lines was noted in three cases.


CONCLUSIONS
Most of the rebleeding occurred within the first post-op week, with gradual reabsorption in the posterior pole within 4 weeks; widespread confluent bleeding might result in severe reproliferation and detachment. A major complication of preretinal bleeding was the formation of preretinal fibrosis. Re-operation achieved a mild VA improvement.
Department of Ophthalmology, National Taiwan University Hospital, and Medical College, National Taiwan University, Taipei, Taiwan.
P-T
PT
Yeh
C-M
CM
Yang
C-H
CH
Yang
D000042:Absorption; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D006801:Humans; D007431:Intraoperative Complications; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012044:Regression Analysis; D012166:Retinal Hemorrhage / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D012189:Retrospective Studies; D012827:Silicone Oils / Q000008:administration & dosage* / Q000009:adverse effects; D014821:Vitrectomy / Q000009:adverse effects / Q000379:methods*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D012827:Silicone Oils; D000068258:Bevacizumab